Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N-demethylation

Clinical Pharmacology and Therapeutics

Volumn 60, Issue 4, 1996, Pages 374-384

  Jones, David R ^a,b   Gorski, J Christopher ^a   Haehner, Barbara D ^a   O'Mara Jr , Edward M ^a   Hall, Stephen D ^a  

^a WISHARD MEMORIAL HOSPITAL   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHOXYMORPHINAN; CYTOCHROME P450; DEXTROMETHORPHAN; DEXTRORPHAN; DRUG METABOLITE; ERYTHROMYCIN; NORLEVORPHANOL; RIFAMPICIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; DEMETHYLATION; DRUG ELIMINATION; DRUG EXCRETION; DRUG METABOLISM; DRUG URINE LEVEL; ENZYME ACTIVITY; GENETIC POLYMORPHISM; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL; VOLUNTEER;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTITUSSIVE AGENTS; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DEXTROMETHORPHAN; DRUG INTERACTIONS; ERYTHROMYCIN; FEMALE; HUMANS; MALE; MICROSOMES, LIVER; MIDDLE AGED; MIXED FUNCTION OXYGENASES; PHENOTYPE; RIFAMPIN;

EID: 0029906605     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(96)90194-0     Document Type: Article

References (28)

1. Watkins PB. Noninvasive tests of CYP3A enzymes. Pharmacogenetics 1994;4:171-84.
2. Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 1992;22:1-21.
3. Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Bacchi CE, et al. Use of midazolam as a human cytochrome P4503A probe; II: characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. J Pharmacol Ther 1994;271:557-66.
4. Lown KS, Thummel KE, Benedict PE, Shen DD, Turgeon DK, Berent S, et al. The erythromycin breath test predicts the clearance of midazolam. Clin Pharmacol Ther 1995;57:16-24.
5. Kahan BD. Cyclosporine. N Engl J Med 1989;321: 1725-38.
6. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences. JAMA 1993;269:1513-8.
7. Williams ML, Lennard MS, Martin IJ, Tucker GT. Interindividual variation in the isomerization of 4-hydroxytamoxifen by human liver microsomes: involvement of cytochromes P450. Carcinogenesis 1994; 15:2733-8.
8. Watkins PB, Murray SA, Winkelman LG, Heuman DM, Wrighton SA, Guzelian PS. Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. J Clin Invest 1989;83:688-97.
9. Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Hartwell PS, et al. Use of midazolam as a human cytochrome P4503A probe; I: in vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther 1994;271:549-56.
10. Schmid B, Bircher J, Preisig R, Kupfer A. Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther 1985;38:618-24.
11. Pfaff G, Briegel P, Lamprecht I. Inter-individual variation in the metabolism of dextromethorphan. Int J Pharm 1983;14:173-89.
12. Gorski JC, Jones DR, Wrighton SA, Hall SD. Characterization of dextromethorphan N-demethylation by human liver microsomes. Biochem Pharmacol 1994;48:173-82.
13. Hebert MF, Ruberts JP, Prueksaritanont T, Benet LZ. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 1992;52:453-7.
14. Chen ZR, Somogyi AA, Bochner F. Simultaneous determination of dextromethorphan and three metabolites in plasma and urine using high-performance liquid chromatography with application to their disposition in man. Ther Drug Monit 1990;12:97-104.
15. Sokol RR, Rohlf FJ. Biometry. 2nd ed. New York: WH Freeman, 1981.
16. Jacqz E, Hall SD, Branch RA. Genetically determined polymorphisms in drug oxidation. Hepatology 1986;6:1020-32.
17. Vetticaden SJ, Cabana BE, Prasad VK, Purich ED, Jonkman JHJ, de Zeeuw R, et al. Phenotypic differences in dextromethorphan metabolism. Pharm Res 1989;6:13-9.
18. Kolars JC, Awni WM, Merion RM, Watkins PB. First pass metabolism of cyclosporine by the gut. Lancet 1991;338:1488-90.
19. Wrighton SA Brian WR, Sari MA Iwasaki M, Guengerich FP, Raucy JL, et al. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5(HLp3). Mol Pharmacol 1990;38:207-13.
20. Lown KS, Kolars JC, Thummel KE, Barnett JL, Kunze KL, Wrighton SA, et al. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel: lack of prediction by the erythromycin breath test. Drug Metab Dispos 1994;22:947-55.
21. Kinirons MT, O'Shea D, Downing TE, Fitzwilliam AT, Joellenbeck L, Groopman JD, et al. Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men. Clin Pharmacol Ther 1993;54:621-9.
22. Mitra AK, Thummel KE, Unadkat JD, Slattery JT. Metabolism of dapsone in human liver by cytochrome P-4502E1 [abstract]. ISSX Proc 1994;6:248.
23. Cakaloglu Y, Devlin J, Tredger JM, Williams R. P450IIIA activity is related to FK 506 and cyclosporine A(CyA) dose in liver transplant recipients. Hepatology 1992;16:56A.
24. Jacqz-Aigrain E, Funck-Brentano C, Cresteil T. CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans. Pharmacogenetics 1993;3: 197-204.
25. Ducharme J, Abdullah S, Wainer IW. Dextromethorphan as an in vivo probe for the simultaneous determination of CYP2D6 and CYP3A activity. J Chrom B 1996;678:113-28.
26. Bartkowski RR, Goldberg ME, Larijani GE, Boerner T. Inhibition of alfentanil metabolism by erythromycin. Clin Pharmacol Ther 1989;46:99-102.
27. Freeman DJ, Martell R, Carruthers SG, Heinrichs D, Keown PA, Stiller CR. Cyclosporine-erythromycin interaction in normal subjects. Br J Clin Pharmacol 1987;23:776-8.
28. Phillips JP, Antal EJ, Smith RB. Pharmacokinetic drug interaction between erythromycin and triazolam. J Clin Psychopharmacol 1986;6:297-9.